Private Equity Round in 2023
Tipalti, Inc. is a provider of accounts payable automation and global mass payments software, designed to streamline payment processes for businesses. Founded in 2010 and headquartered in San Mateo, California, with an additional office in Kibbutz Glil-Yam, Israel, Tipalti offers a comprehensive cloud-based solution that manages the entire payables workflow. This includes supplier onboarding and management, tax compliance, invoice processing, global funds disbursement, and payment reconciliation. The platform is particularly beneficial for sectors such as ad networks, affiliate networks, ecommerce, and online marketplaces, allowing companies to significantly reduce their supplier payment workload by up to 80%. By automating these processes, Tipalti helps businesses scale efficiently while maintaining financial and regulatory compliance, ultimately enhancing the experience for partners and suppliers.
Alladapt Immunotherapeutics, Inc. is a biopharmaceutical company focused on developing therapeutics for food allergies. Founded in 2018 and based in Menlo Park, California, the company is advancing its lead program, ADP101, which aims to provide a broad-spectrum oral immunotherapy treatment. This innovative drug targets the mitigation, treatment, and prevention of food allergies caused by single or multiple proteins from a wide range of common allergens. Through its research and development efforts, Alladapt Immunotherapeutics seeks to enable healthcare providers to effectively address the challenges faced by patients with various food allergies.
Gritstone Bio is a biotechnology company focused on developing personalized cancer immunotherapies aimed at treating various cancer types and infectious diseases. The company is advancing its lead product candidates, GRANITE and SLATE, both of which are in Phase I/II clinical trials. GRANITE targets solid tumors, including metastatic non-small cell lung cancer and gastroesophageal cancer, while SLATE serves as an off-the-shelf immunotherapy for common solid tumors and mutation-positive cancers. Gritstone is committed to identifying therapeutic neo-antigens from individual patients' tumors to create novel treatments, leveraging the expertise of its scientific founders and management team. Founded in 2015 and headquartered in Emeryville, California, the company is also engaged in strategic collaborations to enhance its research and development efforts.
X4 Pharmaceuticals is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing novel therapeutics for primary immune deficiencies and cancer. Its lead drug candidate, mavorixafor, is an oral small molecule antagonist of the chemokine receptor CXCR4 and is currently undergoing various clinical trials, including a Phase III trial for patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, as well as trials for severe congenital neutropenia and clear cell renal cell carcinoma. The company is also advancing X4P-002, which targets glioblastoma multiforme, and X4P-003, aimed at treating primary immune deficiencies. Additionally, X4 Pharmaceuticals has a collaboration with Abbisko Therapeutics to explore mavorixafor in combination with checkpoint inhibitors for oncology applications. Founded in 2014, X4 Pharmaceuticals was previously known as Arsanis, Inc. before rebranding in 2019.
Geron Corporation is a late-stage clinical biopharmaceutical company based in Menlo Park, California, specializing in the development and commercialization of therapeutics for hematologic myeloid malignancies. The company's primary focus is on imetelstat, a first-in-class telomerase inhibitor currently undergoing Phase 2/3 clinical trials. Imetelstat aims to inhibit the uncontrolled growth of malignant progenitor cells in these cancers, which helps reduce the production of dysfunctional blood cells and facilitates the recovery of normal blood cell production. Founded in 1990, Geron is dedicated to advancing innovative treatments for patients with serious blood disorders.
Akero Therapeutics is a clinical-stage biotechnology company based in South San Francisco, California, focused on developing treatments for serious metabolic diseases, particularly nonalcoholic steatohepatitis (NASH). Founded in 2017, the company aims to address high unmet medical needs associated with NASH, a condition characterized by liver inflammation and damage that can lead to severe complications. Akero's lead product candidate, AKR-001, is a long-acting Fc fusion modified FGF21 protein currently undergoing Phase IIa clinical trials. This candidate is designed to restore metabolic balance by reducing liver fat and suppressing inflammation and fibrosis, thereby potentially halting the progression of NASH. The development of AKR-001 builds upon extensive research into FGF21 biology, positioning it as a promising treatment option in a field lacking approved therapies.
Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company that develops and commercializes therapeutic candidates for cardiovascular, metabolic, and liver diseases. The company's lead product, MGL-3196, is an orally administered, small-molecule, liver-directed thyroid hormone receptor β-selective agonist currently in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis (NASH). Additionally, Madrigal is developing MGL-3745, another THR-β-selective small molecule, which is in preclinical trials for NASH and hyperlipidemia. The company aims to address significant unmet medical needs across various conditions, including diabetes and dyslipidemia. Founded in 2011 and headquartered in West Conshohocken, Pennsylvania, Madrigal Pharmaceuticals collaborates with Hoffmann-La Roche to further its research and commercialization efforts.
MiRagen is a biopharmaceutical company that discovers and develops innovative microRNA-targeting therapies to improve human health, specifically in disease areas of high unmet medical need. The company leverages in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance best-in-class technologies and high-potential drug candidates for its own pipeline or in conjunction with strategic partners. The company was founded in 2007 and headquartered in Boulder, Colorado.
Esme Learning Solutions LLC, based in Charlestown, Massachusetts, specializes in providing online learning solutions tailored for executives and working professionals. The company delivers transformational educational experiences through an artificial intelligence-based platform, which facilitates engaging online programs and video conferences. Esme Learning partners with individual executives, universities, and corporations to offer courses on contemporary business trends, including blockchain, fintech, and digital engagement. This approach enables learners to enhance their careers, launch new ventures, and improve their business acumen while accommodating the needs of time-constrained professionals.
Lucira Health develops a new class of professional and home-health solutions to help illuminate and elucidate health status to expedite decision-making and treatment. The company's at-home test kit is well suited for home use and the molecular nucleic acid amplification technology is adaptable to COVID-19 detection. Lucira Health produces inexpensive, disposable health diagnostic hardware that transforms any smartphone into a portable, real-time health-monitoring device for rapid, accessible, multiplexed analysis of bodily fluids anywhere in the world. It enables consumers to take the first step in their healthcare management through at-home diagnosis and a companion mobile app to provide follow up treatment. Lucira Health was founded in 2013 and is headquartered in Emeryville, California, United States.
TG Therapeutics is an innovative, clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. Currently, the company is developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a novel, glycoengineered, third generation monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. TG Therapeutics is headquartered in New York City and is traded on NASDAQ under the ticker symbol "TGTX".
NorthSea Therapeutics B.V. is a biotechnology company based in Naarden, the Netherlands, established in 2017. The company specializes in the development and manufacturing of novel therapeutics aimed at addressing metabolic, inflammatory, and fibrotic diseases. It focuses on creating first-in-class, oral lipid therapeutics through its proprietary Structurally Engineered Fatty Acid (SEFA) technology. One of its key products, icosabutate, is a structurally engineered fatty acid designed to treat inflammatory and liver diseases. The SEFA technology enables the development of candidates that exhibit a range of biological effects, effectively targeting issues such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis across various models.
Carwow Ltd. operates an online platform designed to simplify the process of buying new cars. Founded in 2013 and headquartered in London, the platform connects car buyers with registered dealerships, allowing consumers to compare offers on configured vehicles without the need for haggling. Carwow provides valuable resources including car reviews, advice on choosing the right vehicle, and information on financing and selling cars. By streamlining the buying process and enhancing transparency, Carwow aims to make car purchasing more efficient and cost-effective for consumers while helping dealers improve stock turnover and reduce inefficiencies.
Locus Biosciences is a developer of a CRISPR-engineered precision antibacterial platform designed to revolutionize the treatment of bacterial disease. The company's platform combines the antibacterial power of CRISPR-Cas3 with the efficient, safe delivery of bacterial viruses called bacteriophage, enabling physicians to begin treatment more quickly, resulting in a better medical outcome.
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is headquartered in Waltham, Massachusetts.
Corium International, Inc. is a biopharmaceutical company specializing in the development, manufacture, and commercialization of specialty pharmaceutical products that utilize transdermal and transmucosal delivery systems. The company offers several products, including a clonidine transdermal delivery system for hypertension, fentanyl patches for chronic pain management, and Crest Whitestrips for teeth whitening. Its product pipeline features innovative therapies, such as Twirla, a hormonal contraceptive patch, and a transdermal system for severe osteoporosis. Additionally, Corium is developing transdermal systems for Alzheimer's disease, psychiatric disorders, and motion sickness. The company collaborates with various pharmaceutical partners to advance its product offerings. Established in 1995, Corium International is headquartered in Menlo Park, California, and operates with a focus on enhancing therapeutic outcomes through advanced drug delivery technologies.
Private Equity Round in 2021
3Gtms, Inc. specializes in designing and developing transportation management software solutions for various stakeholders in the logistics sector, including shippers, logistics service providers, and freight brokers. The company's flagship offerings include the Transportation Management Suite, which manages the entire transportation lifecycle from optimization to execution, the Contract Management Suite for cost management, and the LTL Rate Management Suite, which serves as an adaptable alternative to traditional rating tools. 3Gtms focuses on simplifying complex transportation management processes, providing specialized solutions that support quote-to-cash transportation management. The company also offers comprehensive support, training, and consulting services, with both on-premise and cloud-based deployment options available. Founded in 2010 and headquartered in Shelton, Connecticut, 3Gtms has additional offices in Raleigh, North Carolina; Utrecht, the Netherlands; and Wayne, Pennsylvania.
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is based in Buffalo Grove, Illinois.
Better Therapeutics discovers, develops and commercializes prescription digital therapeutics for the treatment of cardiovascular and metabolic diseases. We use clinically-validated, FDA-regulated software to change the behaviors that cause these diseases thereby improving quality of life, reducing the need for medications, and lowering costs. Our products deliver digital behavioral therapy that integrates neuroscience, lifestyle medicine, and explainable AI into a physician-prescribed mobile medical app, and uses patient-generated data to inform clinical decision-making and improve treatment outcomes. Our current product pipeline includes therapeutic candidates for the treatment of type 2 diabetes, hypertension, and dyslipidemia. Our founding team has started, led and exited multiple technology companies that have transformed industries and generated billions of dollars in enterprise value. The 17th Surgeon General of the US, Dr. Richard Carmona, serves as an independent board director. We were founded in 2015 and are headquartered in San Francisco, CA.
Novelion Therapeutics Inc, formerly QLT Inc., is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development. The Company holds a portfolio of products through its subsidiary, Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. The Company's portfolio of products include MYALEPT and JUXTAPID. The Company is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes.
HiberCell, Inc. is a clinical-stage biotechnology company founded in 2019 and based in New York, New York. It is focused on developing innovative therapeutics aimed at preventing cancer relapse and metastasis. The company's pipeline targets adaptive stress pathways and immune modulation to address treatment resistance, which is a significant factor in cancer-related deaths. HiberCell employs advanced artificial intelligence and machine learning techniques to analyze multi-omic and phenotypic profiles of tumors, generating insights that link this data to clinical outcomes. By doing so, HiberCell aims to enhance treatment strategies and ultimately help patients achieve longer, cancer-free lives. The company is supported by prominent investors in the biotechnology sector who share its vision of transforming the approach to metastatic cancer treatment.
Scynexis, Inc. is a biotechnology company based in Jersey City, New Jersey, focused on developing therapies for fungal infections. Its lead product candidate, ibrexafungerp, is an innovative oral and intravenous treatment aimed at addressing a range of fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, and invasive candidiasis, particularly in cases that are refractory to existing treatments. Ibrexafungerp has successfully completed Phase 2 clinical trials for vulvovaginal candidiasis and is characterized as a triterpenoid glucan synthase inhibitor, demonstrating effectiveness against various Candida and Aspergillus species, including drug-resistant strains. Scynexis collaborates with Merck Sharp & Dohme Corp. and R-Pharm, CJSC for the development and commercialization of ibrexafungerp. In addition to its antifungal research, the company engages in drug discovery and development across various therapeutic areas, offering contract research solutions to pharmaceutical and life science partners. Scynexis was founded in 1999 and was previously known as SCYNEXIS Chemistry & Automation, Inc.
Humanigen, Inc. is a clinical-stage biopharmaceutical company based in Burlingame, California, that specializes in the development of proprietary monoclonal antibodies for immunotherapy and oncology. The company's lead product candidate, Lenzilumab, targets granulocyte-macrophage colony-stimulating factor and is currently undergoing Phase Ib/II clinical trials for chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia. Additionally, Humanigen is developing Ifabotuzumab, which targets the EphA3 receptor and has completed the Phase I dose escalation in multiple hematologic malignancies, as well as HGEN005, an anti-EMR1 monoclonal antibody in pre-clinical stages for eosinophilic diseases. The company collaborates with Kite Pharma to conduct a multi-center Phase Ib/II study of Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma and has partnered with the Department of Defense to further develop Lenzilumab for potential emergency use in COVID-19. Founded in 2000, Humanigen was formerly known as KaloBios Pharmaceuticals and rebranded in August 2017.
SingleStore, Inc. is a provider of relational databases designed for both cloud and on-premises transactions and analytics. The company offers the SingleStore Managed Service, a cloud database-as-a-service that facilitates analytics on various cloud platforms, as well as SingleStore DB, a distributed SQL database suitable for operational analytics on bare metal and hybrid cloud environments. SingleStore's solutions include modernizing data platforms, securing government workloads, IoT analytics, and customer interaction management, serving diverse sectors such as financial services, media, energy, government, and retail. Founded in 2011 and headquartered in San Francisco, California, SingleStore also has offices in Seattle, Boston, Portland, Lisbon, and London. Previously known as MemSQL Inc., the company rebranded to SingleStore, Inc. in October 2020.
CloudBolt Software, Inc. specializes in a hybrid cloud management platform that assists enterprises in configuring and managing both private and public cloud resources. Founded in 2012 and headquartered in Rockville, Maryland, with additional offices in various locations, CloudBolt provides an intuitive interface that integrates on-premises resources and public clouds. Its platform empowers organizations by enabling self-service provisioning and effective governance of cloud environments. The company offers solutions that cater to diverse industries, including financial services, healthcare, and technology, helping enterprises optimize automation strategies and manage costs. Key offerings include the CloudBolt platform, OneFuse for codeless integration, and Kumolus for public cloud governance. Through these tools, CloudBolt enables businesses to centralize management and enhance their hybrid cloud capabilities.
Udacity is an online learning platform that specializes in providing educational programs in fields such as artificial intelligence, machine learning, data science, robotics, and cloud computing. Founded in 2011 by David Stavens, Mike Sokolsky, and Sebastian Thrun, the company offers a variety of nanodegree programs designed to equip students with skills that are highly sought after by employers. These programs include training for roles such as web developer, data analyst, and machine learning engineer. Udacity aims to make education more accessible and affordable, thereby helping individuals enhance their career prospects. The platform evolved from free computer science classes offered at Stanford University and has since attracted millions of users. Udacity collaborates with technology companies to ensure that its curriculum aligns with industry demands, thereby preparing learners for the most in-demand tech positions. While the company has not yet turned a profit, it has experienced significant growth and investment, being valued at over $1 billion.
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
AVEO Oncology is a biopharmaceutical company engaged in the development and commercialization of targeted therapies for oncology and other unmet medical needs. The company's lead product, tivozanib, is an oral, once-daily inhibitor of vascular endothelial growth factor receptors, primarily indicated for renal cell carcinoma (RCC). AVEO has completed a Phase III trial (TIVO-3) for tivozanib and is conducting a Phase Ib/II trial combining it with Opdivo, an immune checkpoint inhibitor. Additionally, AVEO is developing Ficlatuzumab, an antibody currently in Phase II trials targeting various cancers, and AV-203, an anti-ErbB3 monoclonal antibody that has completed Phase I trials for esophageal cancer. The company's preclinical pipeline includes AV-380, aimed at cachexia, and AV-353, for pulmonary arterial hypertension. AVEO has established multiple collaboration agreements with various pharmaceutical companies and is involved in clinical trials assessing IMFINZI, an antibody targeting PD-L1. Headquartered in Boston, Massachusetts, AVEO was incorporated in 2001 and has a focus on advancing cancer therapeutics through its proprietary cancer biology platform.
Unity Biotechnology is a biotechnology company dedicated to the research and development of therapeutics aimed at extending human health span by addressing diseases associated with aging. The company specializes in clearing senescent cells through the creation of senolytic medicines, which target vulnerabilities specific to these cells while preserving normal ones. Its lead drug candidates include UBX0101, currently undergoing Phase II trials for musculoskeletal disorders and Phase Ib trials for moderate-to-severe knee osteoarthritis, and UBX1325, which is in Phase I trials for diabetic macular edema. Additionally, Unity is exploring treatments for various age-related conditions, including ophthalmologic, pulmonary, kidney, and liver diseases. Founded in 2009 and based in South San Francisco, California, Unity Biotechnology was formerly known as Forge, Inc. and rebranded in 2015.
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapeutics for cancer treatment. Founded in 2008, the company is headquartered in Research Triangle Park, North Carolina. G1 Therapeutics is advancing several investigational therapies, including trilaciclib, an intravenous cyclin-dependent kinase (CDK) 4/6 inhibitor, currently undergoing Phase 1b/2 trials for extensive-stage small cell lung cancer and Phase 2 trials for first-line small cell lung cancer and metastatic triple-negative breast cancer. The company is also developing lerociclib, an oral CDK4/6 inhibitor, which is in Phase 1b/2a trials for breast cancer and Phase 1b trials for non-small cell lung cancer. Additionally, G1 Therapeutics is progressing rintodestrant, an oral selective estrogen receptor degrader, currently in Phase I/2 trials. The company has partnered with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment in locally advanced breast cancer. G1 Therapeutics aims to improve treatment outcomes for cancer patients through its innovative therapeutic approaches.
SingleStore, Inc. is a provider of relational databases designed for both cloud and on-premises transactions and analytics. The company offers the SingleStore Managed Service, a cloud database-as-a-service that facilitates analytics on various cloud platforms, as well as SingleStore DB, a distributed SQL database suitable for operational analytics on bare metal and hybrid cloud environments. SingleStore's solutions include modernizing data platforms, securing government workloads, IoT analytics, and customer interaction management, serving diverse sectors such as financial services, media, energy, government, and retail. Founded in 2011 and headquartered in San Francisco, California, SingleStore also has offices in Seattle, Boston, Portland, Lisbon, and London. Previously known as MemSQL Inc., the company rebranded to SingleStore, Inc. in October 2020.
ZeroFox is a cybersecurity company based in Baltimore, Maryland, that specializes in protecting organizations from threats arising from social networking and digital communication platforms. The company offers a range of solutions, including real-time social threat analytics, intelligence, and advanced security protection through its cloud-based platform. Its products, such as the ZeroFOX intelligence Livefeed and Protection Cloud, help organizations proactively defend against malware, targeted attacks, and various forms of social engineering, including impersonation and fraud. Additionally, ZeroFox provides services aimed at safeguarding high-value employees and political candidates from targeted threats. The company serves diverse industries, including financial services, healthcare, and technology, by continuously monitoring social media for cyber attacks and information loss. Founded in 2013, ZeroFox has received multiple industry accolades for its innovative approach to cybersecurity.
Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of innovative cancer therapies. Its lead product candidate, entinostat, is a class I HDAC inhibitor currently undergoing Phase III trials for advanced hormone receptor-positive, HER2-negative breast cancer. Additionally, the company is developing SNDX-5613, an inhibitor targeting the Menin-MLL binding interaction, in Phase I/II trials for specific types of acute leukemia. Syndax's pipeline also includes SNDX-6352, a monoclonal antibody designed to block the CSF-1 receptor, which is being tested for chronic graft versus host disease and various solid tumors. The company is pursuing multiple clinical collaborations and agreements with notable organizations, including MSD International and the National Cancer Institute, to enhance its research and development efforts. Founded in 2005, Syndax is dedicated to advancing treatment options for patients with solid tumors and hematological cancers.
ChemoCentryx focuses on discovery, development and commercialization of orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractant receptors.
Their small molecule product candidates is designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inappropriate immune system cascade underlying a given disease.
Dashlane Inc. specializes in password management and secure digital wallet solutions aimed at simplifying and securing users' online identities. Founded in 2009 and based in New York, with additional offices in Paris and Lisbon, Dashlane offers a comprehensive password manager that allows users to import and securely store passwords, autofill forms, and make payments without manual entry. Its features include strong password generation, automatic login, and a digital wallet that captures purchase receipts. Dashlane also provides business solutions designed to enhance password security and mitigate the risks of insecure password sharing. With a user-friendly application available on multiple platforms and in 11 languages, Dashlane has gained the trust of over 10 million users across 180 countries. The company has raised significant venture funding to further develop its offerings for a safer online experience.
Aldeyra Therapeutics is a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's lead investigational drug product candidates are first-in-class potential treatments in development for dry eye disease, allergic conjunctivitis, proliferative vitreoretinopathy, and Sjögren-Larsson Syndrome. The company is also developing other product candidates for retinal and systemic inflammatory diseases.
Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing therapeutics aimed at addressing significant unmet medical needs in cancer treatment, particularly those related to abnormal gene expression and drug resistance. The company's lead product candidates include CPI-0610, currently undergoing Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, which is in Phase Ib/II trials for metastatic castration-resistant prostate cancer alongside androgen receptor signaling inhibitors. Additionally, Constellation is developing CPI-0209, which is in the dose escalation phase of a Phase I/II clinical trial for solid tumors. Founded in 2008, the company was previously known as Epigenetix, Inc. and has established itself as a pioneer in the emerging field of epigenetics, which focuses on selective regulators of epigenetic function crucial for gene expression control.
FuelCell Energy, Inc. specializes in the design, manufacture, installation, operation, and servicing of stationary fuel cell power plants designed for distributed power generation. The company offers a range of products, including those based on carbonate fuel cell technology, which can be configured for on-site power generation, utility grid support, and hydrogen production, among others. FuelCell Energy also provides carbon capture systems that extract carbon dioxide from emissions produced by various industrial sources. The company has approximately 300 megawatts of power generation capacity installed or in backlog and serves diverse sectors such as utilities, industrial operations, healthcare, and government facilities. With a strong presence primarily in the United States, South Korea, England, and Germany, FuelCell Energy has generated over 1.5 billion kilowatt hours of power from renewable biogas and clean natural gas. Headquartered in Danbury, Connecticut, the company is also engaged in ongoing research to advance hydrogen generation and solid oxide fuel cell technology.
TG Therapeutics is an innovative, clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. Currently, the company is developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a novel, glycoengineered, third generation monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. TG Therapeutics is headquartered in New York City and is traded on NASDAQ under the ticker symbol "TGTX".
Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapies for urologic conditions in the United States. The company’s primary product candidate is vibegron, an oral small molecule beta-3 agonist designed to treat overactive bladder (OAB), OAB in men with benign prostatic hyperplasia, and abdominal pain associated with irritable bowel syndrome. Additionally, Urovant is developing URO-902, a gene therapy aimed at patients with OAB who have not responded to oral pharmacological treatments. Founded in 2016 and based in London, Urovant operates as a subsidiary of Sumitovant Biopharma Ltd.
BridgeBio is a biotechnology company dedicated to the discovery, development, and delivery of medicines for genetic diseases. The company has a diverse pipeline of 20 development programs, which range from early discovery to late-stage clinical trials. Among its notable candidates are BBP-265, an oral small molecule targeting transthyretin amyloidosis currently in Phase 3 trials, and infigratinib, a selective tyrosine kinase inhibitor aimed at treating FGFR-driven cancers and achondroplasia. Additionally, BridgeBio is developing BBP-631, a preclinical gene therapy for congenital adrenal hyperplasia, and BBP-454, a program focused on small molecule inhibitors for KRAS-driven cancers. The company collaborates with several prestigious institutions, including Stanford University and Johns Hopkins University, to enhance its research and development efforts. Founded in 2015 and headquartered in Palo Alto, California, BridgeBio aims to accelerate the development of therapies for Mendelian diseases, genetic dermatology, and oncology.
Mesoblast Limited is a biopharmaceutical company focused on developing and commercializing allogeneic cellular medicines for various complex diseases. Headquartered in Melbourne, Australia, the company utilizes its proprietary Mesenchymal Precursor Cell (MPC) technology to address conditions such as cardiovascular disorders, orthopedic spine issues, oncology, hematology, and immune-mediated diseases. Key products in clinical development include MSC-100-IV for steroid refractory acute graft versus host disease, MPC-150-IM for advanced heart failure, and MPC-06-ID for chronic low back pain. Additionally, Mesoblast is advancing MPC-300-IV in Phase II trials for biologic refractory rheumatoid arthritis and diabetic kidney diseases. The company collaborates with partners like Tasly Pharmaceutical Group and JCR Pharmaceuticals to expand its offerings in global markets, including the United States, Australia, Singapore, the United Kingdom, and Switzerland. Founded in 2004, Mesoblast aims to provide innovative therapies where conventional treatments have limited efficacy.
Nabriva Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative anti-infective agents to address serious bacterial infections. The company's lead product, lefamulin, is a semi-synthetic pleuromutilin antibiotic designed to treat community-acquired bacterial pneumonia and acute bacterial skin infections. It is currently undergoing clinical trials for additional applications, including pediatric infections, sexually transmitted infections, osteomyelitis, and prosthetic joint infections. Nabriva is also advancing CONTEPO, an epoxide antibiotic aimed at treating complicated urinary tract infections, and it is in clinical trials for peri-operative prophylaxis. Founded in 2005 and headquartered in Dublin, Ireland, Nabriva Therapeutics has evolved from its earlier identity as a research institute focused on antibiotic development.
Contentful GmbH is a Berlin-based company that provides a cloud-based content management platform designed for web and mobile applications. Established in 2011, it enables enterprises to create and manage digital experiences across multiple channels with enhanced speed and scalability compared to traditional content management systems. Contentful consolidates content into a central hub, allowing it to be structured for various digital platforms while integrating seamlessly with numerous tools via open APIs. Notable clients include Spotify, Urban Outfitters, and The British Museum, who utilize Contentful’s platform to enhance their digital content strategies. The company also offers the Optimizely application, which allows developers to incorporate content experimentation features into their projects. In addition to its headquarters in Berlin, Contentful has offices in San Francisco and Denver.
Acacia Pharma is a hospital pharmaceutical company based in Cambridge, United Kingdom, that specializes in the discovery, development, and commercialization of supportive care drugs for patients undergoing surgery, invasive procedures, or cancer treatments. The company’s lead product, BAREMSIS, is an intravenous formulation of amisulpride designed to prevent and treat post-operative nausea and vomiting. Other notable products include APD403, which has completed Phase II trials for chemotherapy-induced nausea and vomiting, and BYFAVO, an ultra-short-acting intravenous benzodiazepine anesthetic that has completed Phase III trials for use in procedures like colonoscopy and bronchoscopy. Acacia Pharma primarily serves anesthesiologists and oncologists, with a focus on addressing issues related to nausea, vomiting, cancer-related fatigue, and cachexia. Established in 2006, the company continues to innovate in the field of cancer supportive care.
Merrimack Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts, founded in 1993. The company focuses on the discovery, design, and development of innovative therapies for diseases related to autoimmunity and cancer. Its notable products include MM-093, aimed at treating rheumatoid arthritis and psoriasis, and MM-121, a human monoclonal antibody designed to inhibit the ErbB3 receptor signaling. Merrimack employs a systems biology approach, utilizing multidisciplinary capabilities to create predictive computational models of biological systems, particularly in cell signaling networks. Additionally, the company engages in partnerships with third parties to enhance the commercialization of its therapeutics.
TransEnterix, Inc. is a medical device company that focuses on the research, development, and sale of robotic systems designed to enhance minimally invasive surgery. Its primary products include the Senhance System, a multi-port robotic surgery system that utilizes multiple robotic arms for instrument control and camera operation, and the SurgiBot System, a single-port robotically enhanced laparoscopic surgical platform. These systems enable surgeons to perform complex procedures, such as gallbladder removal, with minimal scarring. TransEnterix markets its products directly and through distributors in various regions, including Europe, the United States, Japan, and Taiwan. Founded in 2006, the company is headquartered in Morrisville, North Carolina.
CloudPay Solutions Limited specializes in Software-as-a-Service (SaaS) payroll solutions, providing a comprehensive platform for managed global payroll services tailored for multinational organizations. Established in 1996 and headquartered in Salisbury, United Kingdom, with additional offices in several countries, CloudPay delivers end-to-end payroll management through a unified platform that ensures compliance and consistency across over 130 countries and in more than twenty-five languages. The company’s innovative approach streamlines payroll processes, reduces operational costs, and enhances visibility for organizations, making it a leader in the industry. CloudPay's expertise has been recognized through various awards, including accolades for its technology and service excellence. The company previously operated under the name Patersons Payroll Solutions Limited until its rebranding in 2012.
RumbleON is an online retailer that allows both consumers and dealers to Buy-Sell-Trade-Finance pre-owned motorcycles in an efficient, fast, transparent, and engaging experience. It specializes in Harley-Davidson, e-commerce, recreational vehicles, acquisition, and motorcycles.
Dashlane Inc. specializes in password management and secure digital wallet solutions aimed at simplifying and securing users' online identities. Founded in 2009 and based in New York, with additional offices in Paris and Lisbon, Dashlane offers a comprehensive password manager that allows users to import and securely store passwords, autofill forms, and make payments without manual entry. Its features include strong password generation, automatic login, and a digital wallet that captures purchase receipts. Dashlane also provides business solutions designed to enhance password security and mitigate the risks of insecure password sharing. With a user-friendly application available on multiple platforms and in 11 languages, Dashlane has gained the trust of over 10 million users across 180 countries. The company has raised significant venture funding to further develop its offerings for a safer online experience.
Metalysis Limited is a technology company based in Rotherham, United Kingdom, specializing in the manufacture of high-value metals and alloys, particularly titanium and tantalum. Founded in 2001, the company utilizes a solid-state process originally developed at the University of Cambridge to produce metal alloy powders that are primarily used in advanced manufacturing, aerospace, and automotive applications. This innovative process is designed to be more environmentally friendly and energy-efficient than traditional melting methods, providing clients with lower-cost solutions for producing 3D printable metal powders. Metalysis has established collaborations with various industrial and academic partners to enhance its production capabilities, including the Generation 4 technological expansion, which aims to scale up production to meet industrial demands. In addition to its manufacturing services, Metalysis also offers powder metallurgy, additives, and analytical services.
Gibraltar Business Capital, LLC, established in 1951 and based in Northbrook, Illinois, specializes in providing working capital solutions for small to medium-sized businesses across various industries in the U.S. The firm offers asset-based loans and factoring services, including invoice factoring, revolving lines of credit, and equipment term loans, which are tailored to the specific financial needs of its clients. Gibraltar serves companies with limited operating history, negative cash flow, and those experiencing sales fluctuations. By collaborating with business owners, advisors, and financial sponsors, the company addresses short-term capital challenges and supports growth opportunities. Gibraltar Business Capital is recognized for its flexible and accessible financing alternatives compared to traditional bank loans, allowing businesses to regain financial stability in a dynamic market environment.
Tricida, Inc. is a pharmaceutical company based in South San Francisco, California, established in 2013. The company is dedicated to the development and commercialization of its lead product candidate, TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis, a condition often associated with CKD, can hasten kidney deterioration and lead to serious complications such as muscle wasting and loss of bone density. Tricida has successfully completed a Phase 3, double-blind, placebo-controlled trial of TRC101, which aims to bind and remove acid from the gastrointestinal tract, thereby addressing the underlying metabolic issues and potentially slowing the progression of CKD.
Intuity Medical develops blood glucose monitoring systems for diabetes management. Their POGO Automatic Blood Glucose Monitoring System is the world’s first FDA-cleared automatic, one-step blood glucose meter that combines lancing, blood collection, and analysis into a single 10-test cartridge. It provides a convenient and discreet solution for millions of patients who need to regularly test their blood glucose. The company was founded in 2002 and is headquartered in Fremont, California.
Intuity Medical develops blood glucose monitoring systems for diabetes management. Their POGO Automatic Blood Glucose Monitoring System is the world’s first FDA-cleared automatic, one-step blood glucose meter that combines lancing, blood collection, and analysis into a single 10-test cartridge. It provides a convenient and discreet solution for millions of patients who need to regularly test their blood glucose. The company was founded in 2002 and is headquartered in Fremont, California.
Private Equity Round in 2018
Gynesonics, Inc. is a healthcare company specializing in the development of minimally invasive solutions for symptomatic uterine fibroids in women. The company offers the Sonata System, which utilizes sonography-guided transcervical fibroid ablation to treat these conditions under intrauterine sonography guidance. Founded in 2005, Gynesonics is headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands. The company serves customers worldwide, focusing on providing advanced, incision-free treatment options for uterine conditions.
Myovant Sciences is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for women's health and endocrine diseases. The company's primary product is relugolix, an oral, once-daily medication that functions as a gonadotropin-releasing hormone receptor antagonist, targeting conditions such as heavy menstrual bleeding associated with uterine fibroids, endometriosis-related pain, and advanced prostate cancer. Additionally, Myovant is advancing MVT-602, an oligopeptide kisspeptin agonist aimed at treating female infertility in assisted reproduction. The company collaborates with Pfizer to enhance the development and commercialization of relugolix in both oncology and women's health. Founded in 2016 and based in London, Myovant Sciences was previously known as Roivant Endocrinology Ltd. and currently operates as a subsidiary of Sumitovant Biopharma Ltd.
BioQ Pharma is a specialty pharmaceutical company focused on developing and commercializing a range of ready-to-use infusible pharmaceuticals designed for post-surgical pain management, anesthesia, and sedation. Its product portfolio includes Ropivacaine for pain relief and Propofol for anesthesia, along with pipeline candidates in antibiotics and oncology. The company utilizes a proprietary unit-dose infusion system that enhances safety and efficiency at the point of care, addressing key issues such as medication errors and sterility. BioQ Pharma partners with several organizations, including Novartis' Sandoz unit and Cipla, to market its products across the U.S., European, and Asian markets. Established in 2003 and headquartered in San Francisco, California, BioQ Pharma also has operations in Gent, Belgium. The company was previously known as BioQuiddity Incorporated until its rebranding in 2015.
Sebacia, Inc. is a medical device company based in Duluth, Georgia, specializing in light-based therapies for dermatological conditions, particularly acne. The company aims to provide innovative alternatives to traditional topical and systemic medications by utilizing a patented technology involving gold microparticles. These microparticles are applied to the skin and activated using a standard dermatology laser, selectively targeting the structures involved in acne. Developed in collaboration with researchers from Rice University and the Wellman Center of Photomedicine at Massachusetts General Hospital, Sebacia's approach addresses unmet needs in dermatology while offering a more effective treatment option for those affected by acne. Established in 2008, Sebacia continues to advance its technology with the goal of improving patient outcomes.
Concert Pharmaceuticals is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts, founded in 2006. The company focuses on discovering and developing novel small-molecule drugs primarily for autoimmune and central nervous system disorders. Its key product candidates include CTP-543, currently in Phase III trials for alopecia areata; CTP-692, in Phase II trials for schizophrenia; and AVP-786, which is undergoing Phase III trials for various neurologic and psychiatric conditions, including agitation related to Alzheimer’s disease. Concert employs a unique precision deuterium chemistry platform to modify existing drug molecules, aiming to enhance efficacy and safety while reducing research and development risks. The company also maintains strategic collaborations with several pharmaceutical partners to further its research and development efforts.
Antares Pharma, Inc. is a specialty pharmaceutical company dedicated to developing and commercializing self-administered parenteral pharmaceutical products and technologies across the United States and internationally. The company offers a range of injection products, including OTREXUP, a pre-filled syringe for methotrexate used by patients with rheumatoid arthritis and psoriasis; XYOSTED for testosterone deficiency; and Sumatriptan Injection for migraine treatment. Antares also provides Epinephrine Injection for anaphylaxis and Makena auto injectors to help reduce the risk of preterm birth. Other products include needle-free injectors for administering human growth hormone and disposable pen injectors for diabetes and osteoporosis management. The company has established strategic alliances with various pharmaceutical firms to enhance its product offerings. Founded in 1978 and headquartered in Ewing, New Jersey, Antares Pharma emphasizes improving patient compliance and safety through its innovative technologies.
Verastem Oncology is a biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer. Its portfolio consists of small molecule kinase inhibitors that inhibit critical signaling pathways, which promote cancer cell survival and tumor growth.
908 Devices Inc. is a Boston-based company that develops and sells advanced measurement devices for chemical and biochemical analysis, utilizing mass spectrometry technology. The company's product lineup includes handheld and desktop devices designed for immediate, on-site analysis across various fields such as life sciences, bioprocessing, industrial biotechnology, and forensics. Notable products include the MX908, a portable mass spectrometry device for rapid analysis of unknown substances, the Rebel desktop analyzer for real-time monitoring of bioprocess environments, and the ZipChip, a high-resolution separation platform that enhances mass spectrometry sample analysis. Established in 2012, 908 Devices aims to make mass spectrometry accessible beyond traditional laboratories, providing reliable tools for professionals needing quick and actionable insights. The company operates mainly in the United States while also serving markets in Europe, Asia, and beyond.
Sio Gene Therapies, Inc. is a clinical-stage company dedicated to developing gene therapies for debilitating neurodegenerative diseases. Its key programs include the AXO-Lenti-PD program aimed at treating Parkinson's disease, as well as the AXO-AAV-GM1 and AXO-AAV-GM2 programs targeting GM1 and GM2 gangliosidosis, respectively. The company has established a license agreement with Oxford BioMedica and The University of Massachusetts Medical School to support its research and development efforts. Founded in 2014 and based in New York, Sio Gene Therapies was formerly known as Axovant Gene Therapies Ltd. and adopted its current name in November 2020.
Druva Software Pvt. Ltd. is a provider of data protection and governance solutions tailored for both public and private cloud environments. Founded in 2007 and headquartered in Pune, India, the company offers a range of services, including the inSync platform for enterprise-wide data protection, backup, and governance, as well as Phoenix, a cloud backup and archiving solution designed for remote office servers. Druva's cloud-native platform integrates data from various sources, including endpoints and servers, thereby facilitating data center consolidation, compliance monitoring, and enhanced cyber resiliency. With operations in London, Singapore, and Tokyo, Druva serves various sectors such as healthcare, high technology, manufacturing, consulting, and education, helping organizations reduce costs, improve data accessibility, and streamline governance while mitigating risks and complexities associated with data management.
Mattersight Corporation, a subsidiary of NICE Systems Inc., specializes in enterprise analytics that focuses on customer and employee interactions. The company offers a Behavioral Analytics service that captures and analyzes various forms of interactions, including employee desktop data and contextual information. This service is designed to optimally route customers to agents who are best suited to meet their unique personality styles, thereby enhancing communication outcomes. Mattersight's solutions are utilized by organizations in sectors such as healthcare, telecommunications, finance, and retail to improve operational performance, boost agent effectiveness, and predict future interactions. By facilitating better conversations between customers and agents, Mattersight helps organizations achieve measurable revenue growth and operational efficiencies.
Auris Medical is a biopharmaceutical company focused on developing innovative therapies for the treatment and prevention of disorders affecting the inner ear and central nervous system. Its advanced clinical programs include Keyzilen for acute inner ear tinnitus and AM-111 for acute inner ear hearing loss. The company is also working on AM-125, which is in Phase 2 trials for the intranasal treatment of acute peripheral vertigo, and AM-201, in Phase 1b trials aimed at preventing side effects associated with antipsychotic medications. Additionally, Auris Medical is developing AM-102 for tinnitus treatment. The company collaborates with academic institutions and other entities such as INSERM and Xigen S.A. to enhance its product offerings, including drug delivery devices for local administration to the inner ear. Founded in 1998, Auris Medical is headquartered in Hamilton, Bermuda.
Aprecia Pharmaceuticals, LLC is a pharmaceutical company specializing in the development and manufacture of innovative drug delivery systems. Founded in 2003 and headquartered in Blue Ash, Ohio, the company focuses on advanced technologies such as ZipDose, which provides orodispersible formulations that combine high-dose capabilities with taste-masking options. Aprecia's product portfolio includes SPRITAM, a medication for treating various types of seizures, and CustomRelease, which offers tailored time release profiles for medications. The company also develops NanoDose for submilligram dosing and ImplantaDose for post-surgical management of infections and pain. Aprecia's commitment to transforming patient and caregiver experiences is evident in its use of three-dimensional printing technology to create fast-melt pharmaceutical products. The company's manufacturing facilities are located in East Windsor and New Jersey.
Plug Power Inc. specializes in hydrogen fuel cell solutions for electric mobility and stationary power markets across North America and Europe. The company focuses on advanced proton exchange membrane (PEM) fuel cell technologies and offers a range of products, including GenDrive, a hydrogen PEM fuel cell system for material handling electric vehicles, and GenFuel, which encompasses hydrogen fueling delivery and storage systems. Additionally, Plug Power provides GenCare for ongoing maintenance of its fuel cells, GenSure for modular stationary power solutions, and ProGen, a fuel cell stack used in various applications. With a commitment to creating a green hydrogen ecosystem, Plug Power aims to establish hydrogen highways and deliver sustainable energy solutions across multiple sectors, including telecommunications and transportation. Founded in 1997 and headquartered in Latham, New York, the company serves retail-distribution and manufacturing businesses through direct sales and partnerships with original equipment manufacturers and dealer networks.
Flowonix is a medical device company dedicated to helping those who suffer from chronic disorders. Their team has decades of experience developing unique and reliable medical devices to improve lifestyles. Using one of a kind technology, Flowonix has developed an implantable drug pump designed to deliver therapeutic drugs into the spine to relieve a variety of chronic disorders and help patients return to normal lives.
FuelCell Energy, Inc. specializes in the design, manufacture, installation, operation, and servicing of stationary fuel cell power plants designed for distributed power generation. The company offers a range of products, including those based on carbonate fuel cell technology, which can be configured for on-site power generation, utility grid support, and hydrogen production, among others. FuelCell Energy also provides carbon capture systems that extract carbon dioxide from emissions produced by various industrial sources. The company has approximately 300 megawatts of power generation capacity installed or in backlog and serves diverse sectors such as utilities, industrial operations, healthcare, and government facilities. With a strong presence primarily in the United States, South Korea, England, and Germany, FuelCell Energy has generated over 1.5 billion kilowatt hours of power from renewable biogas and clean natural gas. Headquartered in Danbury, Connecticut, the company is also engaged in ongoing research to advance hydrogen generation and solid oxide fuel cell technology.
ClearObject Corporation is an Internet of Things (IoT) innovator based in Fishers, Indiana, specializing in designing, developing, and managing IoT products and platforms. Founded in 2010, the company offers a range of services, including managed services, professional services, and pilots acceleration, aimed at helping clients integrate and leverage IoT solutions. ClearObject employs a customer-led approach, providing access to a diverse set of expertise, including engineering, analytics, machine learning, and app design. As a certified partner of IBM Watson IoT and Google Cloud Platform, ClearObject utilizes current tools and strategies to assist clients in achieving their IoT objectives and extracting valuable insights from their data. The company was rebranded from CloudOne Corp. in 2017 to emphasize its focus on IoT solutions, and it has since expanded its capabilities with the addition of a Digital Products business unit. ClearObject has received various accolades, including recognition as one of the fastest-growing IT services firms in Indiana.
(NYSE MKT: MSTX) We are a San Diego-based biopharmaceutical company developing proprietary product candidates to treat various diseases and conditions.
Proven by the world's most demanding enterprises, including AAA NCNU, Constant Contact, Falck, Hootsuite, Pitney Bowes, Audi, Adobe, Telekom Denmark, Philips, Roku, and VMware, Aria helps enterprises grow their recurring revenue businesses. Aria helps clients take advantage of each customer-driven event − known as revenue moments − with agile billing, active customer engagement, and the rapid development of new products and services. With Aria's end-to-end active monetization platform, global brands can get to market faster with a wider variety of products and services, while maximizing customer satisfaction, retention, and lifetime value.
CytRx Corporation is a biopharmaceutical company based in Los Angeles, California, that focuses on the research and development of innovative therapies for oncology and rare diseases. The company specializes in creating novel anti-cancer drug candidates, particularly through its linker activated drug release (LADR) technology, which aims to enhance the delivery and effectiveness of cytotoxic agents at tumor sites. CytRx's lead product, aldoxorubicin, is a modified version of doxorubicin designed to target tumors more effectively by binding to circulating albumin in the bloodstream. The company is currently conducting multiple clinical trials, including a Phase 2b trial for soft tissue sarcomas and various studies exploring combinations with other treatments. Additionally, CytRx is expanding its oncology pipeline with other drug candidates, including tamibarotene and bafetinib, and has developed an albumin companion diagnostic product to identify suitable patients for its therapies. Founded in 1985, CytRx continues to advance its mission of delivering impactful treatments for cancer patients.
Modumetal, Inc. develops and manufactures advanced nano-laminated metals designed for a variety of applications across multiple industries, including energy, aerospace, automotive, defense, infrastructure, and construction. Founded in 2006 and based in Seattle, Washington, with a sales office in The Woodlands, Texas, the company specializes in producing corrosion-resistant alloys that are lighter, stronger, and more durable than traditional metals. By utilizing low-cost electrochemical methods to grow metals, Modumetal creates materials that enhance structural integrity and thermal performance. Their product offerings include customized alloys, fasteners, pumps, valves, and production tubulars, all aimed at improving asset returns and reducing corrosion in diverse production environments. This innovative approach to material science positions Modumetal as a leader in the development of high-performance materials that can replace conventional metals and composites.
Gynesonics, Inc. is a healthcare company specializing in the development of minimally invasive solutions for symptomatic uterine fibroids in women. The company offers the Sonata System, which utilizes sonography-guided transcervical fibroid ablation to treat these conditions under intrauterine sonography guidance. Founded in 2005, Gynesonics is headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands. The company serves customers worldwide, focusing on providing advanced, incision-free treatment options for uterine conditions.
Proterra Inc. designs and manufactures zero-emission electric buses, specializing in heavy-duty vehicles that enable fleet operators to reduce operating costs and eliminate fossil fuel dependency. The company’s product lineup includes 35-foot and 40-foot Catalyst transit vehicles, which are built to meet the diverse mileage needs of urban and regional routes on a single charge. Proterra also provides a range of services, including pre-delivery consultations, training programs, mid-life inspections, and battery management services. Their offerings extend to energy services such as fleet planning, charging infrastructure, and telematics. Founded in 2004 and headquartered in Burlingame, California, Proterra has additional offices in South Carolina and California, and its products are designed, engineered, and manufactured in the United States. By helping customers transition to battery-electric transit solutions, Proterra has contributed to significant reductions in greenhouse gas emissions and fuel consumption.
Proterra Inc. designs and manufactures zero-emission electric buses, specializing in heavy-duty vehicles that enable fleet operators to reduce operating costs and eliminate fossil fuel dependency. The company’s product lineup includes 35-foot and 40-foot Catalyst transit vehicles, which are built to meet the diverse mileage needs of urban and regional routes on a single charge. Proterra also provides a range of services, including pre-delivery consultations, training programs, mid-life inspections, and battery management services. Their offerings extend to energy services such as fleet planning, charging infrastructure, and telematics. Founded in 2004 and headquartered in Burlingame, California, Proterra has additional offices in South Carolina and California, and its products are designed, engineered, and manufactured in the United States. By helping customers transition to battery-electric transit solutions, Proterra has contributed to significant reductions in greenhouse gas emissions and fuel consumption.
Zosano Pharma Corporation is a clinical stage biopharmaceutical company based in Fremont, California, established in 2006. The company specializes in developing therapeutics for migraine sufferers through its innovative intracutaneous microneedle delivery system. Its primary product candidate, Qtrypta (M207), is a proprietary formulation of zolmitriptan aimed at treating migraines. Zosano Pharma is committed to discovering and developing drug candidates that meet significant unmet medical needs and have strong commercialization potential.
Machine Zone, Inc. is a developer of mobile games that focuses on creating free-to-play social gaming experiences. Founded in 2008 and originally named Addmired, the company rebranded in 2012 and is headquartered in Sunnyvale, California. Machine Zone specializes in various game genres, including fantasy, role-playing, and massively multiplayer online games. Its games are available on multiple platforms, including Android and iOS devices. The company aims to provide entertainment through multiplayer experiences, utilizing a live global data ecosystem that connects players across linguistic and geographic barriers, allowing for competition and collaboration on a global scale.
ReachLocal, Inc. specializes in providing online marketing solutions for small and medium-sized businesses across various regions, including North America, Europe, and Asia-Pacific. The company offers a comprehensive suite of services, including search engine marketing, search engine optimization, display advertising, and retargeting strategies to enhance online visibility. Key products include ReachSearch for search engine advertising, ReachDisplay for display ads, and ReachRetargeting for engaging past website visitors. Additionally, ReachLocal's ReachEdge software helps businesses convert leads into customers and analyze their marketing return on investment. Other offerings encompass web presence management, reputation management, and social media marketing tools. The company also provides a managed local listings service and the TotalLiveChat widget for real-time customer interaction. Founded in 2003 and headquartered in Woodland Hills, California, ReachLocal operates as a subsidiary of Gannett Co., Inc. and continues to support local businesses in optimizing their digital marketing efforts.
Agile Therapeutics, Inc. is a women's healthcare company dedicated to developing and commercializing prescription contraceptive products. The company’s lead product, Twirla, is a once-weekly transdermal contraceptive patch that delivers a low dose of levonorgestrel and ethinyl estradiol. Agile Therapeutics is also advancing a pipeline of related products, including various line extensions of Twirla and additional transdermal contraceptive options. These include regimens designed to extend menstrual cycles or provide shorter and lighter periods, as well as a progestin-only patch intended for women who cannot or prefer not to use estrogen. Founded in 1997 and headquartered in Princeton, New Jersey, Agile Therapeutics aims to address the unmet healthcare needs of women through innovative contraceptive solutions.
SparkPost offers a cloud-based email infrastructure platform that allows applications and websites to efficiently send and receive emails. With a client base that includes prominent companies like Pinterest, LinkedIn, and Twitter, SparkPost facilitates the delivery of over 5 trillion messages annually, accounting for more than 37 percent of the world's commercial email. The platform is designed to meet diverse email delivery needs, integrating messaging with various data sources and applications to enable real-time two-way interactions. SparkPost is recognized for its high deliverability, reliability, and data insights, which are essential for enhancing customer engagement across different businesses.
SparkPost offers a cloud-based email infrastructure platform that allows applications and websites to efficiently send and receive emails. With a client base that includes prominent companies like Pinterest, LinkedIn, and Twitter, SparkPost facilitates the delivery of over 5 trillion messages annually, accounting for more than 37 percent of the world's commercial email. The platform is designed to meet diverse email delivery needs, integrating messaging with various data sources and applications to enable real-time two-way interactions. SparkPost is recognized for its high deliverability, reliability, and data insights, which are essential for enhancing customer engagement across different businesses.
Message Systems is a computer software company providing email infrastructure, authentication, security, and marketing services.
Melinta Therapeutics, Inc. is a commercial-stage pharmaceutical company specializing in the discovery, development, and commercialization of anti-infective therapies targeting bacterial infections. The company offers several products, including Baxdela, Vabomere, Orbactiv, and Minocin, which address various acute bacterial skin infections and gram-negative infections. Recognizing the urgent need for new antibiotics to combat drug-resistant infections, Melinta is advancing delafloxacin, currently in Phase 3 development for treating acute bacterial skin and skin structure infections. The company also focuses on developing innovative antibiotics aimed at overcoming resistant pathogens associated with serious hospital infections. Established in 2000, Melinta Therapeutics is headquartered in Morristown, New Jersey, and operates with support from strategic partners in the healthcare sector.
The AspireAssist™ is a breakthrough weight loss solution for people with obesity. Unlike many other weight loss procedures, it's minimally-invasive and reversible. The AspireAssist is now commercially available in selected regions in Europe and beyond, and is currently in clinical trials across the US.
Cerulean Pharma Inc. is a privately-held biopharmaceutical company focused on developing innovative therapeutics utilizing nanotechnology, particularly in the fields of oncology, cardiovascular, autoimmune, and inflammatory diseases. The company specializes in nanoparticle-drug conjugates, which are designed to specifically target tumors, reduce toxicity, and facilitate drug combinations. Among its product offerings is Ovaprene, a non-hormonal contraceptive that provides extended protection. Cerulean Pharma has assembled a distinguished team, including a management team, board of directors, and scientific advisory board, all of whom possess extensive experience in business development and scientific research from prominent organizations and institutions.
Bellicum Pharmaceuticals is a clinical-stage biopharmaceutical company based in Houston, Texas, focused on developing innovative cellular immunotherapies for the treatment of hematological cancers and solid tumors. The company is advancing its product candidates, including BPX-601, an autologous GoCAR-T therapy aimed at solid tumors expressing prostate stem cell antigen, and BPX-603, a dual-switch GoCAR-T therapy targeting solid tumors that express human epidermal growth factor receptor 2. Bellicum utilizes its proprietary Chemical Induction of Dimerization technology platform, which allows for real-time control of immune system components to enhance therapeutic efficacy. The company collaborates with various institutions, including Adaptimmune Therapeutics and Baylor College of Medicine, to further its research and development efforts. Founded in 2004, Bellicum Pharmaceuticals continues to make strides in cancer treatment through its novel immunotherapeutic approaches.
MELA Sciences is a medical technology company dedicated to designing and developing innovative software-driven technologies that assist physicians during the clinical evaluation and detection of skin cancer. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.
Dynavax Technologies Corporation is a biopharmaceutical company headquartered in Emeryville, California, specializing in the discovery and development of novel vaccines and treatments for infectious diseases. The company markets HEPLISAV-B, an adjuvanted vaccine for the prevention of hepatitis B infection in adults. Dynavax utilizes its unique Toll-like Receptor Immune Modulation Platform to stimulate the body's immune responses, which is integral to its product development. In addition to its commercial offerings, Dynavax has an active immuno-oncology portfolio, featuring candidates such as SD-101 and DV281. The company is engaged in various research collaborations aimed at developing COVID-19 vaccines, partnering with organizations like Clover Biopharmaceuticals, the University of Queensland, and CEPI. These partnerships reflect Dynavax's commitment to addressing urgent health challenges through innovative vaccine solutions. Founded in 1996, Dynavax has evolved from its original name, Double Helix Corporation, to focus on enhancing immune responses for better disease prevention and treatment.
ADMA Biologics, Inc. is a biopharmaceutical company focused on developing, manufacturing, and marketing specialty plasma-derived biologics aimed at treating immune deficiencies and infectious diseases in the United States. The company's product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin products indicated for primary humoral immunodeficiency, as well as Nabi-HB, which treats acute exposure to Hepatitis B. ADMA also has a pipeline of therapeutics targeting infections such as S. pneumonia. To support its production, ADMA operates FDA-licensed source plasma collection facilities, known as ADMA BioCenters, which supply plasma for its products. The company distributes its offerings through independent distributors, sales agents, and specialty pharmacies. Founded in 2004 and headquartered in Ramsey, New Jersey, ADMA Biologics is dedicated to serving niche patient populations, particularly those who are immune-compromised due to underlying conditions or medical treatments.
Soasta, Inc. is a digital performance management company based in Mountain View, California, specializing in cloud testing, performance testing, real user monitoring, and application testing for web and mobile environments. Established in 2006, the company offers a suite of products, including mPulse for real user monitoring, CloudTest for load and performance testing, TouchTest for mobile functional testing, and a Digital Operations Center for performance visibility. Soasta's platform enables businesses to gain real-time insights into user experiences, allowing them to optimize performance and align it with business objectives. The company has conducted over 10 million tests and measured more than 100 billion user experiences, serving a diverse clientele that includes notable names in various industries. Additionally, Soasta provides comprehensive support services, including strategic assessments, test planning, execution, and training options for clients. As of 2017, Soasta operates as a subsidiary of Akamai Technologies.
MELA Sciences is a medical technology company dedicated to designing and developing innovative software-driven technologies that assist physicians during the clinical evaluation and detection of skin cancer. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.
nContact, Inc. is a medical device company specializing in the development of innovative solutions for the treatment of cardiac arrhythmias, particularly atrial fibrillation. Founded in 2005 and based in Morrisville, North Carolina, the company focuses on minimally invasive ablation procedures. Its flagship product, the Numeris Coagulation System with VisiTrax, utilizes a unique combination of suction, perfusion, and radiofrequency energy to create visible, nonconductive lesions on the epicardium of a beating heart. This system has received regulatory approval for use in the United States and holds CE Mark approval in Europe. nContact also offers a range of other devices designed to ensure consistent contact with cardiac tissue, facilitating effective lesion creation. The company has initiated clinical studies to further explore its technology's application in treating atrial fibrillation through both open and closed chest procedures. In 2011, nContact, formerly known as nContact Surgical, became a subsidiary of AtriCure, Inc.
Flowonix is a medical device company dedicated to helping those who suffer from chronic disorders. Their team has decades of experience developing unique and reliable medical devices to improve lifestyles. Using one of a kind technology, Flowonix has developed an implantable drug pump designed to deliver therapeutic drugs into the spine to relieve a variety of chronic disorders and help patients return to normal lives.
Gamma Medica, Inc. specializes in digital molecular imaging devices focused on early breast cancer detection. The company is recognized for its LumaGEM® MBI System, the first commercially available, FDA-cleared imaging system that employs cadmium zinc telluride (CZT) technology. This innovative planar, dual-head, fully solid-state system is designed to identify millimeter-sized breast cancers that are often overlooked by traditional mammography, particularly in women with dense breast tissue. In addition to the LumaGEM system, Gamma Medica offers a range of imaging technologies, including digital X-ray mammography, tomography, 3D mammography, and ultrasound systems, all aimed at enhancing screening capabilities for dense breast tissue and promoting early-stage cancer prevention.
ChromaDex Corporation is a nutraceutical company focused on promoting healthy aging through innovative ingredients and scientific research. It is best known for its flagship product, Nicotinamide riboside (NIAGEN), a form of vitamin B3 that helps enhance levels of nicotinamide adenine dinucleotide (NAD+), which naturally decline with age. The company also offers Immulina, a spirulina extract aimed at boosting immune function. ChromaDex operates through three primary segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services, with the bulk of its revenue generated from the Consumer Products segment. The company is involved in developing and commercializing patented ingredient technologies for various markets, including dietary supplements, food, beverages, skincare, and pharmaceuticals. Alongside its product offerings, ChromaDex provides analytical testing and regulatory consulting services, reinforcing its commitment to quality and safety in its ingredient development. Headquartered in Los Angeles, California, ChromaDex continues to leverage its extensive intellectual property and scientific backing in the biosciences sector.
Edge Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies for acute neurological conditions, particularly in hospital settings. Founded in 2009 and based in Berkeley Heights, New Jersey, the company aims to transform treatment paradigms for serious medical conditions with significant unmet needs. Its lead product candidate, EG-1962, is currently being evaluated in the Phase 3 NEWTON 2 study for the treatment of aneurysmal subarachnoid hemorrhage, a condition resulting from bleeding around the brain due to a ruptured aneurysm. Additionally, Edge is developing EG-1964 as a potential prophylactic treatment for chronic subdural hematoma, aiming to prevent recurrent bleeding on the brain's surface. The company employs its proprietary Precisa platform to create polymer-based therapeutics that deliver treatment directly to the site of injury, minimizing impact on surrounding tissues.